Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 3/20 | 0.49 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872828 | 0.87 | CBFB (0.39) | CBFBMETAP2METAP1GUSBKDM4E | |
| SCHEMBL6883125 | 0.85 | CXCR4 (0.42) | METAP2METAP1KDM4ENPC1MAPT | |
| SCHEMBL11372223 | 0.84 | CBFB (0.33) | CBFBMETAP2METAP1GUSBKDM4E | |
| SCHEMBL10616888 | 0.81 | CBFB (0.40) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL10616882 | 0.81 | CXCR4 (0.33) | CBFBMETAP2METAP1KDM4ENPC1 | |
| SCHEMBL10620031 | 0.81 | METAP2 (0.52) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL10617516 | 0.81 | CBFB (0.41) | CBFBMETAP2MAPTPOLB | |
| SCHEMBL10617524 | 0.81 | CBFB (0.52) | CBFBMETAP2PDE10ATRPV1 | |
| SCHEMBL6442907 | 0.81 | METAP2 (0.41) | METAP2METAP1GUSBKMT2AMEN1 | |
| SCHEMBL6454112 | 0.74 | METAP2 (0.50) | CBFBMETAP2METAP1GUSBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | claimed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | claimed |
| US-4045563-A | Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects | AB HASSLE (SW) | 1977-08-30 | — | — | US | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-1572098-A2 | METHOD OF TREATING SNORING AND OTHER OBSTRUCTIVE BREATHING DISORDERS | Sohn, Stearns & Stern (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| WO-2004034973-A2 | METHOD OF TREATING SNORING AND OTHER OBSTRUCTIVE BREATHING DISORDERS | STERN WARREN (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | CBFB 2690/4885METAP2 1609/4885METAP1 2557/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | CBFB 2903/4885METAP2 127/4885METAP1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.